Aclaris Therapeutics (ACRS) Income from Continuing Operations (2014 - 2026)

Aclaris Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 20678000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 29.9% year-over-year to 20678000.0; the TTM figure through Mar 2026 stood at 73498000.0 (up 44.72% YoY), while the FY2025 annual figure was 68738000.0, up 47.95% from the prior year.
• Income from Continuing Operations was 20678000.0 for Q1 2026 at Aclaris Therapeutics, up from 21100000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 1858000.0 in Q4 2023 to a low of 97572000.0 in Q4 2024.
• Historically, Income from Continuing Operations has averaged 23888294.12 across 5 years, with a median of 20678000.0 in 2026.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 93.61% in 2023, then slumped 5151.45% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 29079000.0 in 2022, then soared by 93.61% to 1858000.0 in 2023, then plunged by 5151.45% to 97572000.0 in 2024, then surged by 78.37% to 21100000.0 in 2025, then increased by 2.0% to 20678000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 20678000.0 (Q1 2026), 21100000.0 (Q4 2025), and 15330000.0 (Q3 2025), per Business Quant data.